FTC Accuses Drug Middlemen Of Raising Insulin Prices

By Matthew Perlman · September 20, 2024, 12:00 PM EDT

The Federal Trade Commission on Friday accused the three largest pharmacy benefits managers, Caremark Rx, Express Scripts and OptumRx, of artificially inflating insulin prices by relying on unfair rebate schemes that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Matthew

November 20, 2024
PBMs Sue To Block FTC's In-House Insulin Pricing Case
November 07, 2024
Teva Can't End Inhaler Antitrust Suit But Gets Claim Nixed
November 01, 2024
Health Data Co. Urges 4th Circ. To Keep Access Open
October 31, 2024
Drug Cos. To Pay $49M For State-Led Generic Pricing Claims
October 30, 2024
Ohio PBM Case Will Wait For High Court Ruling
October 24, 2024
PBMs Want Separate FTC Hearings Over Insulin Prices
October 21, 2024
NC Justices Revive Challenge To Hospital Competition Law
October 15, 2024
FTC Wants More Info On $1.36B Home Healthcare Deal
October 07, 2024
Justices Won't Hear Shkreli's Bid To Undo $64M Disgorgement
September 23, 2024
Medical Records Co. Accused Of Blocking Data Access